# Regeneron Pharmaceuticals (REGN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/REGN
## Company Profile
- Ticker: REGN
- Exchange: NASDAQ
- Sector: Antibody Drugs, Biopharma
- Location: United States
- Tags: Antibody Drugs, Oncology, Immunology
## Stock Data
- Close: 797.99 USD
- Market cap: 63209549173.439995 USD
- Last updated: 2026-08-12
## Business Overview
### Integrated Biopharmaceutical Company
Regeneron Pharmaceuticals discovers, develops, manufactures and commercializes medicines across ophthalmology, immunology, oncology, rare disease, cardiovascular medicine and other areas. Its internal technology platforms support a large clinical portfolio and multiple global collaborations.
### Retinal Disease Franchise
EYLEA and EYLEA HD are anti-VEGF therapies used in retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema. EYLEA HD offers extended dosing intervals and anchors Regeneron’s ophthalmology business.
### Dupixent Collaboration
Dupixent is an IL-4 receptor alpha antibody developed globally with Sanofi across type 2 inflammatory diseases. Its indications span dermatologic, respiratory and allergic conditions, including recent expansions into pediatric chronic spontaneous urticaria and allergic fungal rhinosinusitis.
### Oncology Pipeline
Regeneron commercializes the PD-1 antibody Libtayo and is developing fianlimab, a LAG-3 antibody, with cemiplimab in metastatic and adjuvant melanoma. The company’s oncology strategy combines proprietary antibodies across complementary immune pathways.
### Rare-Disease Medicines
Otarmeni is an approved AAV gene therapy for OTOF-related severe-to-profound hearing loss. Garetosmab, an Activin A antibody, is under regulatory review for fibrodysplasia ossificans progressiva, while cemdisiran is an siRNA therapy submitted for myasthenia gravis.
### Cardiovascular and Metabolic Programs
REGN7508 and REGN9933 are Factor XI antibodies in Phase 3 development for thrombosis prevention. Mibavademab is a leptin-receptor agonist antibody in Phase 3 testing for monogenic obesity.
## Why The Stock Is Moving

As of Aug 12, 2026, REGN was little changed and closed at $797.99. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA decisions on EYLEA HD prefilled-syringe manufacturing applications anticipated in the second quarter of 2026.
- Phase 3 first-line metastatic-melanoma results for fianlimab plus cemiplimab expected in the second quarter of 2026.
- Second interim or final analysis of the adjuvant-melanoma fianlimab study expected in the second half of 2026.
- FDA action on the garetosmab BLA for FOP targeted for August 2026.
- FDA filing acceptance for cemdisiran anticipated in the second quarter of 2026, with a decision expected in the fourth quarter.
- Additional Phase 3 Factor XI antibody studies planned later in 2026.

## Recent News
- 2026-07-31 11:00 EST — [Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation](https://biopharmsignal.com/news/REGN/regeneron-awards-150-000-to-winners-of-the-2026-regeneron-prize-for-creative-inn-b562f013) — Source: Regeneron Pharmaceuticals
- 2026-07-30 10:30 EST — [Regeneron Reports Second Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/REGN/regeneron-reports-second-quarter-2026-financial-and-operating-results-39145cc1) — Source: Regeneron Pharmaceuticals
- 2026-06-25 20:05 EST — [Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast](https://biopharmsignal.com/news/REGN/regeneron-to-report-second-quarter-2026-financial-and-operating-results-and-host-c2e371f6) — Source: Regeneron Pharmaceuticals
- 2026-06-22 11:00 EST — [Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)](https://biopharmsignal.com/news/REGN/cemdisiran-regulatory-submissions-accepted-for-review-by-fda-and-ema-for-the-tre-c71f8f44) — Source: Regeneron Pharmaceuticals
- 2026-06-04 11:00 EST — [Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO](https://biopharmsignal.com/news/REGN/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo) — Source: Regeneron Pharmaceuticals